B-Cell Non-Hodgkin Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory
Conditions
Brief summary
A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LUCAR-G39D, a dual-targeted cell preparation targeting CD19/CD20, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Detailed description
This is an open-label, dose-escalation/dose extension study to assess the safety, tolerability, and efficacy of LUCAR-G39D in the patient ≥ 18 years of age with relapsed or refractory B-cell non-Hodgkin lymphoma. Subjects who meet the eligibility criteria will receive a single dose of LUCAR-G39D injection. The study will include the following sequential phases: screening, pre-treatment (lymphodepleting chemotherapy), treatment, and follow-up.
Interventions
BIOLOGICALLUCAR-G39D cells product
Prior to infusion of the LUCAR-G39D, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
Sponsors
Nanjing Legend Biotech Co.
Tianjin Medical University Cancer Institute and Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects have fully understood the possible risks and benefits of participating in this study, are willing to follow and able to complete all trial procedures, and have signed informed consent. 2. Aged 18-75 years (inclusive). 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. Histologically confirmed B-cell non-Hodgkin Lymphoma that expresses at least one of CD19/CD20. 5. At least one evaluable tumor lesion according to Lugano 2014 criteria. Response to prior therapy is consistent with one of the following: 1. Primary refractory. 2. Relapsed or refractory after 2 or more lines of therapy. 3. For LBCL, 3B FL. t-iNHL: * Relapse within 12 months after first-line chemoimmunotherapy to achieve CR; * Progression or relapse within 12 months after autologous hematopoietic stem cell transplantation; 7\. Life expectancy≥ 3 months 8. Clinical laboratory values meet screening visit criteria
Exclusion criteria
Subject eligible for this study must not meet any of the following criteria: 1\. Prior antitumor therapy with insufficient washout period ; 2. Patients who received autologous CAR-T cell therapy (except CD19-targeted) or autologous gene therapy; 3. Patients who received allogeneic hematopoietic stem cell transplantation or allogeneic therapy; 5. Patients who are positive for any index of hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), or human immunodeficiency virus antibody (HIV- Ab). 6\. Known life-threatening allergies, hypersensitivity, or intolerance to LUCAR-G39D CAR-T cell or its excipients, including DMSO. 7\. Pregnant or lactating women;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence, severity and type of TEAEs (Treatment-emergent Adverse Events) | Through study completion , an average of 2 years after LUCAR-G39D infusion (Day 1) | An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. |
| Pharmacokinetics in peripheral blood | Through study completion , an average of 2 years after LUCAR-G39D infusion (Day 1). | CAR positive T cells and CAR transgene levels in peripheral blood after LUCAR-G39D infusion. |
| Pharmacokinetics in bone marrow | Through study completion , an average of 2 years after LUCAR-G39D infusion (Day 1) | CAR positive T cells and CAR transgene levels in bone marrow after LUCAR-G39D infusion. |
| The recommended Phase II dose (RP2D) for this cell therapy | Within 30 days after LUCAR-G39D infusion | RP2D established through ATD+BOIN design and the DLTs occurring following CAR T-cell infusion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response (DoR) | Through study completion, an average of 2 years after LUCAR-G39D infusion (Day 1) | Duration of Remission (DoR) is defined as the time from the first documentation of remission (CR or PR) to the first documented relapse evidence of the responders. |
| Overall Response Rate (ORR) | Through study completion, an average of 2 years after LUCAR-G39D infusion (Day 1) | Objective Response Rate (ORR) is defined as the proportion of subjects who achieve CR or PR after treatment via LUCAR-G39D cell infusion |
| Immunogenicity assessment of LUCAR-G39D cells | Through study completion, an average of 2 years after LUCAR-G39D infusion (Day 1) | The incidence of Anti- LUCAR-G39D antibody in patients who received LUCAR-G39D cells infusion |
| Progression-free survival (PFS) | Through study completion, an average of 2 years after LUCAR-G39D infusion (Day 1) | Progression Free Survival (PFS) is defined as the time from the date of first infusion of the LUCAR-G39D to the first documented disease progression (according to Lugano 2014) or death (due to any cause), whichever occurs first |
| Overall Survival (OS) | Through study completion, an average of 2 years after LUCAR-G39D infusion (Day 1) | Overall Survival (OS) is defined as the time from the date of first infusion of LUCAR-G39D to death of the subject |
| Time to Response (TTR) | Through study completion, an average of 2 years after LUCAR-G39D infusion (Day 1) | Time to Response (TTR) is defined as the time from the date of first infusion of LUCAR-G39D to the date of the first response evaluation of the subject who has met all criteria for CR or PR. |
Countries
China
Contacts
Primary ContactHuilai Zhang
Backup ContactKaiyang Ding
Outcome results
None listed